182 related articles for article (PubMed ID: 36350008)
1. EIF3H stabilizes CCND1 to promotes intrahepatic cholangiocarcinoma progression via Wnt/β-catenin signaling.
Wei Y; Chen W; Li Z; Xie K; Liu F
FASEB J; 2022 Dec; 36(12):e22647. PubMed ID: 36350008
[TBL] [Abstract][Full Text] [Related]
2. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
Zhang Y; Xu H; Cui G; Liang B; Chen X; Ko S; Affo S; Song X; Liao Y; Feng J; Wang P; Wang H; Xu M; Wang J; Pes GM; Ribback S; Zeng Y; Singhi A; Schwabe RF; Monga SP; Evert M; Tang L; Calvisi DF; Chen X
Gastroenterology; 2022 Aug; 163(2):481-494. PubMed ID: 35489428
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA MIR22HG inhibits cell proliferation and migration in cholangiocarcinoma by negatively regulating the Wnt/β-catenin signaling pathway.
Hu X; Tan Z; Yang Y; Yang P
J Gene Med; 2019 May; 21(5):e3085. PubMed ID: 30856284
[TBL] [Abstract][Full Text] [Related]
4. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
Sasaki M; Sato Y; Nakanuma Y
Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
[TBL] [Abstract][Full Text] [Related]
5. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway.
Zhang H; Dong X; Ding X; Liu G; Yang F; Song Q; Sun H; Chen G; Li S; Li Y; Wang M; Guo T; Zhang Z; Li B; Yang L
J Transl Med; 2023 Dec; 21(1):900. PubMed ID: 38082327
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA myocardial infarction associated transcript promotes the proliferation of cholangiocarcinoma cells by targeting miR-551b-3p/CCND1 axis.
Chang W; Wang Y; Li W; Geng Z
Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):1067-1075. PubMed ID: 32064660
[TBL] [Abstract][Full Text] [Related]
7. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Wnt signaling induces cell apoptosis and suppresses cell proliferation in cholangiocarcinoma cells.
Zhang KS; Zhou Q; Wang YF; Liang LJ
Oncol Rep; 2013 Sep; 30(3):1430-8. PubMed ID: 23799613
[TBL] [Abstract][Full Text] [Related]
9. The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma.
Liu J; Ren G; Li K; Liu Z; Wang Y; Chen T; Mu W; Yang X; Li X; Shi A; Zhao W; Xu B; Chang J; Guo S; Pan C; Zhou T; Zhang Z; Xu Y
Cell Death Differ; 2022 Apr; 29(4):818-831. PubMed ID: 34799729
[TBL] [Abstract][Full Text] [Related]
10. Deubiquitinase OTUB2 promotes intrahepatic cholangiocarcinoma progression by stabilizing the CTNNB1-ZEB1 axis.
Wang J; Dong Y; Wei Z; Zhang Y; Wu N; Zhang C; Zhang Y; Zi R; Hao J; Liang H; Chen J
Exp Cell Res; 2023 Apr; 425(1):113537. PubMed ID: 36858343
[TBL] [Abstract][Full Text] [Related]
11. Sevoflurane inhibits cholangiocarcinoma via Wnt/β-catenin signaling pathway.
Cheng H; Li Q
BMC Gastroenterol; 2023 Aug; 23(1):279. PubMed ID: 37568083
[TBL] [Abstract][Full Text] [Related]
12. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
Zhang GF; Qiu L; Yang SL; Wu JC; Liu TJ
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32140709
[TBL] [Abstract][Full Text] [Related]
13. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
[TBL] [Abstract][Full Text] [Related]
14. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
15. Activated macrophages promote Wnt/β-catenin signaling in cholangiocarcinoma cells.
Loilome W; Bungkanjana P; Techasen A; Namwat N; Yongvanit P; Puapairoj A; Khuntikeo N; Riggins GJ
Tumour Biol; 2014 Jun; 35(6):5357-67. PubMed ID: 24549785
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma.
Xue W; Dong B; Zhao Y; Wang Y; Yang C; Xie Y; Niu Z; Zhu C
Cell Oncol (Dordr); 2021 Dec; 44(6):1351-1361. PubMed ID: 34796468
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ClC-5 suppresses proliferation and induces apoptosis in cholangiocarcinoma cells through the Wnt/β-catenin signaling pathway.
Shi Z; Zhou L; Zhou Y; Jia X; Yu X; An X; Han Y
BMB Rep; 2022 Jun; 55(6):299-304. PubMed ID: 35651328
[TBL] [Abstract][Full Text] [Related]
18. Guanine nucleotide exchange factor T exerts the cancer-promoting function in cholangiocarcinoma by enhancing the Wnt-GSK-3β-β-catenin cascade via regulation of Rac1/Cdc42.
Wang X; Zhang X; Sun J; Sun Y; Zhang Y; He L; Wang P; Li F; Sun C
Toxicol Appl Pharmacol; 2023 May; 467():116492. PubMed ID: 36977438
[TBL] [Abstract][Full Text] [Related]
19. The pathways of genetic transformation in cholangiocarcinogenesis.
Serafini FM; Radvinsky D
Cancer Genet; 2016 Dec; 209(12):554-558. PubMed ID: 27720541
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
An J; Kim D; Oh B; Oh YJ; Song J; Park N; Kim HI; Kang HJ; Oh JH; Kim W; Lee E; Sung CO; Song GW; Kim DG; Yu E; Letouzé E; Zucman-Rossi J; Lee HC; Shim JH
Hepatology; 2022 Apr; 75(4):997-1011. PubMed ID: 34478159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]